02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
17:21 , Apr 13, 2018 |  BC Week In Review  |  Financial News

Abpro planning $69M NASDAQ listing

Antibody company Abpro Corp. (Woburn, Mass.) filed on April 12 to raise up to $69 million in an IPO on NASDAQ underwritten by UBS, Wells Fargo, Nomura and Oppenheimer. Abpro's two lead programs, ABP-100 and...
17:20 , Apr 12, 2018 |  BC Extra  |  Financial News

Abpro planning $69M NASDAQ listing

Antibody company Abpro Corp. (Woburn, Mass.) filed to raise up to $69 million in an IPO on NASDAQ underwritten by UBS, Wells Fargo, Nomura and Oppenheimer. Abpro's two lead programs, ABP-100 and ABP-201, are designed...